Although continuous glucose monitoring (CGM) devices are now considered the standard of care for people with type 1 diabetes mellitus, the uptake among people with type 2 diabetes mellitus (T2DM) has been slower and is focused on those receiving intensive insulin therapy. However, increasing evidence now supports the inclusion of CGM in the routine care of people with T2DM who are on basal insulin-only regimens or are managed with other medications. Expanding CGM to these groups could minimize hypoglycaemia while allowing efficient adaptation and escalation of therapies. Increasing evidence from randomized controlled trials and observational studies indicates that CGM is of clinical value in people with T2DM on non-intensive treatment regimens. If further studies confirm this finding, CGM could soon become a part of routine care for T2DM. In this Perspective we explore the potential benefits of widening the application of CGM in T2DM, along with the challenges that must be overcome for the evidence-based benefits of this technology to be delivered for all people with T2DM.

尽管连续血糖监测 (CGM) 设备现在被认为是 1 型糖尿病患者的标准治疗方法，但 2 型糖尿病 (T2DM) 患者的使用速度较慢，并且主要集中于接受强化胰岛素治疗的患者。然而，现在越来越多的证据支持将 CGM 纳入仅接受基础胰岛素治疗或接受其他药物治疗的 T2DM 患者的常规护理中。将 CGM 扩展到这些群体可以最大限度地减少低血糖，同时允许有效的适应和升级治疗。越来越多的随机对照试验和观察性研究证据表明，CGM 对于采用非强化治疗方案的 T2DM 患者具有临床价值。如果进一步的研究证实这一发现，CGM 可能很快就会成为 T2DM 常规护理的一部分。在本视角中，我们探讨了扩大 CGM 在 T2DM 中的应用的潜在好处，以及为使该技术为所有 T2DM 患者带来基于证据的好处必须克服的挑战。